Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%^*

References

• Carroll SC, Gaskin BJ, Goldberg I, et al. Glaucoma prescribing trends in Australia and New Zealand. Clin Exper Ophthalmol 2006;34:213–8
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Kaufman PL. Prostaglandin F2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389–402
   PubMed Web of Science ®Google Scholar
• Nilsson SS, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypo-tension caused by prostaglandin F2a-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989;48:707–16
   PubMed Web of Science ®Google Scholar
• Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2a-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F₂a. Arch Ophthalmol 1987;105:1112–6
   Google Scholar
• Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res 1995;23:519–25
   PubMedGoogle Scholar
• Sharif NA, Crider JY, Husain S, et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocular Pharmacol Ther 2003;19:437–56
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary muscle cells. Invest Ophthalmol Vis Sci 1997;38: 2772–80
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retinal Eye Res 2000;19:271–95
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar C, Kaufman PL. Prostaglanin F2a effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci 1995;36: 2461–5
   Google Scholar
• Van Alphen GW, Wilhelm PB, Elsenfeld PW. The effect of prostaglandins on the isolated internal muscles of mammalian eye, including man. Doc Ophthalmol 1977;42:394–415
   Google Scholar
• Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone and other FP prostaglandin receptor agonist analogs. Invest Ophthalmol Vis Sci 2003;44:715–21
   Google Scholar
• Toris CB, Camras CB, Zhan G, et al. Effect of travoprost on diurnal and nocturnal aqueous humor dynamics in patients with ocular hypertension and glaucoma. Poster presented at: the American Glaucoma Society, March, 2005, Snowbird, UT
   Google Scholar
• DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84–91
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55–63
   PubMed Web of Science ®Google Scholar
• Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132: 860–8
   Google Scholar
• The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120: 1268–79
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• Tarkkanen A, Leikola J. Postural variations of the intraocular pressure as measured with the Mackay–Marg tonometer. Acta Ophthalmol 1967;45:569–75
   PubMed Web of Science ®Google Scholar
• Friberg TR, Sanborn G, Weinreb RN. Intraocular and episcleral venous pressure increase during inverted posture. Am J Ophthalmol 1987;103:523–6
   Google Scholar
• Tsukahara S, Sasaki T. Postural change of IOP in normal persons and in patients with primary wide open-angle glaucoma and low tension glaucoma. Br J Ophthalmol 1984;68:389–92
   PubMed Web of Science ®Google Scholar
• Buchanan RA, Williams TD. Intraocular pressure, ocular pulse pressure, and body position. Am J Optom Physiol Opt 1985;62:59–62
   PubMedGoogle Scholar
• Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134–42
   PubMed Web of Science ®Google Scholar
• Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960; 64:494–501
   PubMed Web of Science ®Google Scholar
• Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 2005;139:320–4
   Google Scholar
• Hirooka K, Shiraga F. Relationship between postural change of the intraocular pressure and visual field loss in primary open-angle glaucoma. J Glaucoma 2003;12:379–82
   PubMed Web of Science ®Google Scholar
• Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389–95
   Google Scholar
• Konstas AGP, Mikropoulos D, Kaltsos K, et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446–50
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003;121:453–7
   PubMed Web of Science ®Google Scholar